EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mesenchymal Stromal Cell Therapy in Lung Transplantation

Antti I Nykänen iD, Mingyao Liu iD, Shaf Keshavjee

Bioengineering · 17.06.2023 · 10 (6) · 728

DOI: 10.3390/bioengineering10060728 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 17.06.2023. Verfasst von Antti I Nykänen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Latner Thoracic Surgery Research Laboratories, Toronto General Research Hospital Institute, University Health Network, Toronto, ON M5G 1L7, Canada. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The study was Supported by Canadian Institutes of Health Research (CIHR) Open Operating Grant, Canadian Institutes of Health Research (CIHR), Sigrid Juselius Foundation Fellowship Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung transplantation is often the only viable treatment option for a patient with end-stage lung disease. Lung transplant results have improved substantially over time, but ischemia-reperfusion injury, primary graft dysfunction, acute rejection, and chronic lung allograft dysfunction (CLAD) continue to be significant problems. Mesenchymal stromal cells (MSC) are pluripotent cells that have anti-inflammatory and protective paracrine effects and may be beneficial in solid organ transplantation. Here, we review the experimental studies where MSCs have been used to protect the donor lung against ischemia-reperfusion injury and alloimmune responses, as well as the experimental and clinical studies using MSCs to prevent or treat CLAD. In addition, we outline ex vivo lung perfusion (EVLP) as an optimal platform for donor lung MSC delivery, as well as how the therapeutic potential of MSCs could be further leveraged with genetic engineering.

Schlagwörter

Stichwörter der Autor:innen

cell therapyex vivo lung perfusiongene therapylung transplantationmesenchymal stromal cell

Autor:innen und Institutionen

  • Latner Thoracic Surgery Research Laboratories, Toronto General Research Hospital Institute, University Health Network, Toronto, ON M5G 1L7, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Department of Cardiothoracic Surgery, Helsinki University Hospital and University of Helsinki, FI-00029 Helsinki, Finland.

ORCID-Profile: Antti I Nykänen, Mingyao Liu

Förderung

  • The study was Supported by Canadian Institutes of Health Research (CIHR) Open Operating Grant
  • Canadian Institutes of Health Research (CIHR)
  • Sigrid Juselius Foundation Fellowship Grant

Zitieren

APA

Nykänen, A. I., Liu, M., & Keshavjee, S. (2023). Mesenchymal Stromal Cell Therapy in Lung Transplantation. Bioengineering, 10(6), 728. https://doi.org/10.3390/bioengineering10060728

Vancouver

Nykänen AI, Liu M, Keshavjee S. Mesenchymal Stromal Cell Therapy in Lung Transplantation. Bioengineering. 2023;10(6):728. doi:10.3390/bioengineering10060728

BibTeX
@article{Nyknen2023,
  author = {Nykänen, Antti I and Liu, Mingyao and Keshavjee, Shaf},
  title = {Mesenchymal Stromal Cell Therapy in Lung Transplantation},
  journal = {Bioengineering},
  year = {2023},
  volume = {10},
  number = {6},
  pages = {728},
  doi = {10.3390/bioengineering10060728}
}
Kostenlos starten →